Document is current
Any future updates will be listed below
-
Authors
Mittendorf, Kathleen F.
Lewis, Hannah S.
Duenas, Devan M.
Eubanks, Donna J.
Gilmore, Marian J.
Goddard, Katrina A. B.
Joseph, Galen
Kauffman, Tia L.
Kraft, Stephanie A.
Lindberg, Nangel M.
Reyes, Ana A.
Shuster, Elizabeth
Syngal, Sapna
Ukaegbu, Chinedu
Zepp, Jamilyn M.
Wilfond, Benjamin S.
Porter, Kathryn M.
-
Funding
Funding for this research was provided by:
National Human Genome Research Institute (U01HG007292)
National Cancer Institute (R01CA132829)
National Institutes of Health (T32GM007748)
- License Information
-
More Information
Article History
Received: 8 February 2022
Accepted: 30 May 2022
First Online: 10 June 2022
Declarations
:
: The KPNW Institutional Review Board (IRB) approved this study and all collaborating IRBs ceded to KPNW or approved the study separately. Participants were consented to the CHARM study as well as a separate consent for the interview.
: No individual person’s data in any form (including any individual details, images or videos) are contained within this article.
: KFM declares institutional funding from GE Healthcare for unrelated research. PREMM® is a registered trademark of Dana-Farber Cancer Institute (DFCI). SS receives inventor portion of royalties from licensing revenues paid to DFCI. For unrelated work, SS has previously received consulting fees from Myriad Genetics, Inc. and payment for expert testimony from Glaxo-Smith Kline, Inc.
